Vaccine slows loss of insulin production in type 1 diabetes genetic subgroup
In a Phase II trial, injecting GAD-alum into the lymph nodes of newly diagnosed type 1 diabetes patients with a genetic variant slowed insulin production degradation.
List view / Grid view
News
UK approves Janssen COVID-19 Vaccine
The Janssen COVID-19 Vaccine has been granted conditional marketing authorisation for use in people aged 18 and over in the UK.
FDA approves sotrovimab for emergency use in treating COVID-19
The FDA granted emergency use authorisation to the monoclonal antibody sotrovimab as a treatment for mild-to-moderate COVID-19 in certain adult and paediatric patients.
Researchers may know the cause of COVID-19 vaccine related blood clots
Investigators at the Goethe University of Frankfurt believe that post-transcriptional modifications may be causing the clotting problems associated with recombinant vector COVID-19 vaccines.
Could medicinal cannabis be the answer to the opioid crisis?
New data from the UK shows 86 percent of pain patients found medicinal cannabis more effective than any other medication, including opioids.
Anti-PD-L1 monoclonal antibody shows promise in lung cancer patients
In a Phase III trial sugemalimab meaningfully improved progression free survival in patients with stage III non-small cell lung cancer (NSCLC).
Competition and Markets Authority investigating AstraZeneca’s Alexion acquisition
The UK’s competition authority will assess whether AstraZeneca’s acquisition of Alexion will result in a “substantial lessening of competition”.
Erleada® improves survival without damaging quality of life in prostate cancer trial
Data shows metastatic castration-sensitive prostate cancer patients treated with Erleada® (apalutamide) were 35 percent less likely to die and had maintained quality of life.
International Society for Stem Cell Research (ISSCR) releases new guidelines
The ISSCR has released updated guidelines for stem cell research and clinical translation of stem cell-based therapies.
First patient dosed with multi-variant second-generation COVID-19 vaccine
The first-in-human trial of OSE Immunotherapeutics’ multi-variant, second-generation COVID-19 vaccine has enrolled and dosed its first participant.
EU’s Medical Device Regulation is now applicable
Europe’s Medical Device Regulation is now applicable to medicines with an integral device, devices containing an ancillary medicinal substance and several other products.
Moderna’s COVID-19 vaccine 93 percent effective in adolescents
New Phase II/III study data shows Moderna’s COVID-19 vaccine is safe and immunogenic in patients aged 12 to less than 18 years old.
Talquetamab shows promise in multi-drug refractory multiple myeloma patients
New Phase I data shows 65 percent of triple-class and 83 percent of penta-drug refractory multiple myeloma patients responded to talquetamab.
Pegcetacoplan safe and effective in paroxysmal nocturnal haemoglobinuria trial
In a Phase III study pegcetacoplan resulted in 86 percent of treatment-naïve paroxysmal nocturnal haemoglobinuria (PNH) patients achieving haemoglobin stabilisation.
Global nebulisers market to decline after COVID-19
As the world recovers from COVID-19, research suggests the nebuliser devices market will initially shrink before recovering and reaching a value of $1.55 billion in 2025.
